North America Protein Therapeutics Market

North America Protein Therapeutics Market Size (2024 to 2029)

As per the research report, the North America Protein Therapeutics Market size is valued at USD 66.86 billion in 2024. It is expected to grow at a CAGR of 6.1% to reach USD 89.90 billion by 2029. It captures 35% of the global market.

High Y-o-Y growth rate in the prevalence of cancer and chronic diseases is a key driver propelling the protein therapeutics market growth in North America. Growing acquisition of drugs, raising consciousness regarding the protein therapeutics, and technological advancements in developing new products further fuelled the market growth. Growing discretionary expenses, high particularity, and immunogenicity protein therapeutics are used to treat different diseases such as cancer, diabetes, and multiple sclerosis paired with the government initiatives towards healthcare infrastructure and quick industrialization are predicted to favor the protein therapeutics market in North America.

The High costs associated with the protein therapeutics and unfavorable reimbursement policies are estimated to impede the market growth a little extent.

This research report segmented and sub-segmented into the following categories:

• By Product: Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone
• By Application: Metabolic Disorders, Immunologic Disorders, Haematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Others
• By Therapeutic Modalities: Protein Diagnostics, Protein Vaccines, Protein Therapeutics With Special Targeting Activity, Protein Therapeutics With Enzymatic Or Regulatory Activity
• By Country: U.S., Canada, and Rest of North America

Regionally, North America raked in the highest revenue in  2023, and this trend is likely to continue in the forecast period.

The U.S. is the leader in North America and is expected to retain its dominance in the upcoming years. Significant growth and enhancements in medical technologies, improved diagnosis of the diseases, and enlargement of healthcare in existing markets support this market in the United States. 

The Canadian is projected to showcase a prominent growth rate from 2024 to 2029 and is the second leading market followed after the USA. License termination and an increase in competition among the key players is to boost the market. Moreover, advancing manufacturing technologies also accelerate the market. Proper funds and investments for research and development activities towards the protein therapeutics are likely to mount the market.A widee range of protein therapeutics applicationh involves cancer, genetic disorders, infectious diseases, and metabolic disorders.

Companies playing a dominant role in the North America Protein Therapeutics Market profiled in this report are Baxter International Inc., Eli Lilly and Company, Abbott Laboratories, Amgen Inc., F. Hoffmann-La Roche Ltd. Other players in the market are Novo Nordisk A/S, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., and Sanofi.